Skip to content

New patient pricing is live · From $149/mo, flat at every dose · Free to start

Peptides

CJC-1295, Sermorelin, and Ipamorelin Compared

Three peptides studied for growth hormone signaling, three different mechanisms. Here is how CJC-1295, sermorelin, and ipamorelin differ in plain English.

By Toned Team · Reviewed by the Toned editorial team

Published April 22, 2026 · Last reviewed July 7, 2026 · 2 min read

CJC-1295, sermorelin, and ipamorelin are three peptides studied for their effects on growth hormone signaling — but they are not the same thing, and they are not interchangeable. Sermorelin and CJC-1295 nudge the pituitary through the growth-hormone-releasing-hormone pathway; ipamorelin works through a separate receptor as a growth-hormone-secretagogue. Understanding the difference is the point of this guide.

What is sermorelin, the short-acting GHRH analog?

Sermorelin is an analog of growth-hormone-releasing hormone (GHRH). It signals the pituitary to release growth hormone in a pulse that mimics the body's own pattern, then clears quickly. Its short duration is both its appeal — a more natural, pulsatile signal — and its practical limitation.

How does CJC-1295, the longer-acting GHRH analog, differ?

CJC-1295 is also a GHRH analog, but modified to last considerably longer in the body. Research has documented prolonged elevation of growth hormone and IGF-1 signaling compared with shorter-acting compounds. The trade-off is that a longer, flatter signal departs further from the body's natural pulsatile rhythm. CJC-1295 is covered here for education only — it is not part of Toned's offering.

Why does ipamorelin work on a different receptor entirely?

Ipamorelin is not a GHRH analog. It is a selective growth-hormone-secretagogue that acts on the ghrelin/GHS receptor, a separate pathway, which is why it is sometimes discussed alongside a GHRH analog rather than instead of one. It was characterized as one of the first highly selective secretagogues. Toned does not currently offer ipamorelin; it is covered here for education only.

So which one should you use?

None of them without a clinician. These peptides overlap in goal but differ in mechanism, duration, and appropriateness, and human evidence varies across them. Treat this comparison as a map of the landscape, not a recommendation — and if growth hormone signaling is something you want to explore, do it with a licensed provider. For repair-focused peptides discussed in similar circles, see our BPC-157 research overview and the peptide glossary. What Toned prescribes today is compounded GLP-1 medication.

References

  1. Teichman SL et al. Prolonged stimulation of GH and IGF-I by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006. PubMed
  2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed
  3. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. PubMed
  4. Hedegaard MA, Holst B. The complex signaling pathways of the ghrelin receptor. Endocrinology. 2020. PubMed
  5. Abizaid A, Hougland JL. Ghrelin signaling: GOAT and GHS-R1a take a LEAP in complexity. Trends Endocrinol Metab. 2020. PubMed

This article is for general education and is not medical advice. Talk to a licensed provider about your individual situation.

FAQ

Questions this article answers.

More questions answered in the full FAQ.

Your future self says hi.

Five minutes online today. A licensed provider handles the rest — and you never sit in a waiting room.

Get started — it's free

Takes ~5 min · 100% online · No insurance needed